 Home > Biochemistry News > Biotechnology News > Targeting CD4 legendary biological CAR-T therapy starts clinical trials in the United States

Targeting CD4 legendary biological CAR-T therapy starts clinical trials in the United States

 Last Update: 2021-09-19
 Source: Internet
 Author: User

Tags

light phase

cell express

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On September 13, 2021, Legend Biotech announced that based on the IND application approved by the US FDA, it will start a phase 1 clinical trial of the cell therapy LB1901 under investigation for the treatment of relapsed/refractory peripheral T cell lymph in adults Tumor (PTCL), or skin T-cell lymphoma (CTCL)

TCL is a group of heterogeneous lymphoid malignancies

This open-label, multi-center phase 1 trial will evaluate the safety and tolerability of LB1901 in patients with relapsed/refractory PTCL or relapsed/refractory CTCL expressing CD4, and determine the optimal dose

Image source: Legendary Bio's official website

Reference materials:

[1] Legend Biotech Begins Phase 1 Clinical Trial in the US to Evaluate Investigational Anti-CD4 CAR-T Therapy for Relapsed or Refractory T-Cell Lymphoma.

(The original text has been deleted)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express targeting CD4, legendary biological CAR-T therapy starts clinical trials in the United States

10-01

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Targeting CD4 legendary biological CAR-T therapy starts clinical trials in the United States

Related Articles

Express targeting CD4, legendary biological CAR-T therapy starts clinical trials in the United States